Figure 2: Psychopharmacologic Treatment algorithm for moderate to severe generalized, anxiety disorder in adults (A) and in children and adolescents (B).

Cooler colors represent higher levels of evidence and reflect greater evidence of tolerability and safety. Trials of SSRI and SNRIs should be ≥8 weeks, although if there is no response by week 8, there is a low likelihood of additional improvement. In the pediatric population, clinicians should note that for buspirone, guanfacine, antihistamines, and maintenance administration of benzodiazepines, the evidence base is very weak or conflicting. SSRI, selective serotonin reuptake inhibitor; SNRI, selective serotonin norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant.